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Results:
Table:
Direct stenting
Conventional
stenting
Provisional
stenting p value
PCI success 194/196(99%) 199/201 (99%) 199/200 (99.5%) 0.874
Stent
implantation
192/196 (98.0%) 199/201 (99.0%) 155/200 (77.5%) 0.001
9 month
follow-up
QCA MLD, mm 2.12 0.58 2.17 0.67 1.99 0.69 0.059
MACE 18/192 (9.4%) 9/197 (4.6%) 17/197 (8.6%) 0.152
Conclusions: Direct drug-eluting stenting did not reduce restenosis, when compared tot
conventional DES stenting. Provisional stenting was associated with a higher rate of
restenosis, however, no differences was observed in the rate of MACE during 9-month
follow-up, The 2 year clinical follow-up will be presented at the conference.
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Background: In the drug-eluting-stent (DSE) era, the rate of in-stent restenosis (ISR)
was substantially decreased. Previous randomized trials have suggested that DES
implantation may be efficacious to decrease incidence of repeated ISR. The purpose of this
study was to assess the efficacy of DES implantation for the treatment of ISR after
bare-metal stent (BMS) or DES implantation.
Methods: A total of 120 consecutive patients who developed ISR was included in this
study. Angiographical follow-up was performed in 78 of 120 patients (BMS 67, DES 53).
We compared the angiographical restenosis rate between the patients who underwent
percutaneous coronary intervention (PCI) using DES (DES group) and the patients who
underwent PCI using balloon angioplasty (balloon group).
Results: Overall rate of re-ISR was significantly lower in DES group than in balloon
group (16% vs, 39%, p0.05). In the subset of patients with BMS restenosis (n41), rate
of re-ISR between DES group and POBA group (17% vs, 24%, pNS). On the other
hand, ISR patients after DES implantation (n37) showed significantly lower rate of
re-ISR in DES group than that in POBA group (17% vs, 53%, p0.05).
Conclusions: The efficacy of DES implantation for the treatment of ISR might be
affected by the index stent types.
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Background: The safety and efficacy of the first generation cobalt chromium
everolimus-eluting stent (EES) have been demonstrated in several trials. The PROMUS
Element (Boston Scientific, Natick, Massachusetts) stent is a new generation EES, made
of platinum chromium alloy with thin strut designed to improve radial strength,
radiopacity, vessel conformability, fracture resistance, side-branch access and deliverabil-
ity. We aim to compare the long-term safety and efficacy of this novel PtCr-EES with the
first generation cobalt chromium EES (CoCr-EES) in patients who received them.
Methods: We analyzed retrospectively 788 patients who received PtCr-EES(n378) or
CoCr-EES (n410) from our centre cardiovascular database. The primary endpoint was
the one-year composite major adverse cardiac events (MACE) that include cardiac death,
myocardial infarction, target vessel revascularization and stent thrombosis.
Results: The mean age of the cohort was 58.710.1 years with males constituting 82.7%.
Diabetes mellitus was present in 322 (40.0%) patients. The majority (63.1%) of the lesions
treated were of AHA/ACC Type B2/C. The mean lesion length in the 2 groups were
26.1412.19 mm (PtCr-EES) vs 24.1411.86 (CoCr-EES), p0.009 respectively; and
the stent length were 31.2714.38mm (PtCr-EES) vs 31.2314.61mm (CoCr-EES),
p0.96 respectively. At one year, the results were as follow:
CoCr-EES
(n 410)
PtCr-EES
(n378) p value
Death 9 (2.2%) 12(3.2%) 0.394
Myocardial infarction 16 (3.9%) 9 (2.4%) 0.223
TVR 11 (2.7%) 9 (2.4%) 0.788
MACE 24 (5.9%) 22 (5.8%) 0.984
Stent Thrombosis 8 (2.0%) 5 (1.3%) 0.489
Conclusions: Our study showed that PtCr-EES stent, when used in real-world popula-
tion, showed similar efficacy as the first generation EES at 1 year with no safety concerns
related to the novel stent material and design. The TVR rate is low at 3% for both
groups.
TCT-630
ENERGY 1’000 Subject Registry with a Thin Strut Bare Metal Stent with
Passive Coating Presenting one Year MACE Data on Pre-Specified Subgroups
Raimund Erbel1, Holger Eggebrecht1, Ariel Roguin2, Erwin Schroeder3,
Thomas Heitzer4, Sebastian Philipp5, Oded Ayzenberg6, Harald Schwacke7,
Antonio Serra8, Ton Slagboom9
1German Heart Center, Essen, Germany, 2Rambam Medical Center, Haifa, Israel,
3Cliniques Universtaires UCL de Mont-Godinne, Yvoir, Belgium, 4Klinikum
Dortmund, Dortmund, Germany, 5Elbekliniken Stade-Buxtehude GmbH, Stade,
Germany, 6Kaplan Medical Center, Rehovot, Israel, 7Diakonissen-Stiftungs-
Krankenhaus Speyer, Speyer, Germany, 8Hospital Santa Creu i Sant Pau,
Barcelona, Spain, 9Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
Background: The aim of this registry is to evaluate the clinical performance of a new
generation thin strut bare metal stent (BMS) in a large patient population with
pre-specified subgroups in standard clinical care.
Methods: Between Apr 09, and Nov 11, 2010, 1’016 subjects presenting with de-novo
and restenotic coronary artery lesions were consecutively enrolled in this international,
multicentric ENERGY Registry using a new generation BMS (PRO-Kinetic Energy) in
48 sites in 10 countries. Safety endpoints were MACE at 6 and 12 month FUP. QoL
(EQ-5D) evaluation was performed in a subgroup for all FUP intervals. Pre-specified
subgroups were diabetes, acute myocardial infarction (AMI), small vessels and elderly
subjects ( 75 yrs).
Results: The biggest subgroup was presented by AMI with 46% followed by elderly
29%, small vessel 26% and diabetes 17%. 90.7 percent (922/1’016) follow up compliance
at twelve-month follow-up was achieved. Database not locked yet.
AMI N
470
Elderly N
297
Small
vessel N
251
Diabetes
N 168
Male 79% 65% 73% 77%
Age 63.6
13.3
80.30 4.2 68.2 12 68.7 11
Smoker 59% 45% 57% 61%
Diabetes 6% 19% 19% 100%
B2/C type
lesions
47% 45% 37% 38%
Average stent
length (mm)
16.6 4.9 15.5 4.4 16.1 4.8 15.4 3.8
Mean Stent
diameter
(mm)
3.2 0.5 3.1 0.5 2.7 0.4 3.1 0.4
MACE
hierarchical
6.2% 6.5% 9.2% 7.4%
Cardiac
Death
1.2% 1.8% 1.3% 1.4%
MI 1.4% 1.8% 2.6% 2.0%
clinically
driven TLR
3.6% 2.9% 5.2% 4.1%
MACE rates for all subgroups are not statistically significant different (p0.05).
Conclusions: This new generation BMS with very thin struts and passive coating shows
excellent results through all subgroups, also confirmed in low MACE rates for AMI,
elderly, small vessels and diabetic subjects. Utility of such modern BMS platforms are still
very relevant in the era of DES.
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